121193-16-6

Basic information

• Product Name: Benzoyl chloride, 4-cyclohexyl-
• CAS NO: 121193-16-6
• Molecular Formula: C13H15ClO
• Molecular Weight: 222.715
• Mol File: 121193-16-6.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: Benzoyl chloride, 4-cyclohexyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoyl chloride, 4-cyclohexyl-(121193-16-6)
• EPA Substance Registry System: Benzoyl chloride, 4-cyclohexyl-(121193-16-6)

Safety Data

• Hazardous Substances Data: 121193-16-6(Hazardous Substances Data)

Upstream product

• 85418-99-1 4-cyclohexylaniline hydrochloride 
• 27634-88-4 4-cyclohexyl-1-cyanobenzene 
• 20029-52-1 4-cyclohexylbenzoic acid 

Downstream Products

• 92863-34-8 4-cyclohexylbenzoic acid methyl ester 
• 27634-89-5 4-cyclohexylbenzaldehyde 
• 1004785-87-8 methyl 3-[(4-cyclohexylbenzoyl)amino]thiophene-2-carboxylate 
• 27634-87-3 4-cyclohexyl-benzoic acid amide 
• 1255653-40-7 2-(6-(benzylamino)-2-(4-cyclohexylbenzamido)-9H-purin-9-yl)acetic acid 
• 1255653-38-3 2-(6-(butyl(methyl)amino)-2-(4-cyclohexylbenzamido)-9H-purin-9-yl)acetic acid 
• 1255653-36-1 ethyl 2-(2-(4-cyclohexylbenzamido)-6-(N-morpholino)-9H-purin-9-yl)acetate 
• 1255653-34-9 ethyl 2-(6-(benzylamino)-2-(4-cyclohexylbenzamido)-9H-purin-9-yl)acetate 
• 1255653-32-7 ethyl 2-(6-(butyl(methyl)amino)-2-(4-cyclohexylbenzamido)-9H-purin-9-yl)acetate 
• 1255653-30-5 ethyl 2-(6-chloro-2-(4-cyclohexylbenzamido)-9H-purin-9-yl)acetate 
• 1207192-74-2 C₂₁H₂₃F₃N₂O₃S 

Relevant articles and documents

Molecular parameters and mesomorphism of discotic polysubstituted benzene derivatives

The previously developed approach to prediction of columnar and nematic mesophases for compounds with disc-shaped molecules was applied to low-molecular-weight polysubstituted benzene derivatives. The molecular parameters were calculated for 39 new compounds: derivatives of 1,3,5-tri(4-hydroxybenzoyloxy)benzene, 1,3,5-tri(4-cyclohexylbenzoyloxy)benzene, 1,3,5-tri(4-hydroxyphenylcarboxy)benzene, 1,2,3-tri(4-cyclohexylbenzoyloxy) benzene, etc. The prediction results were checked by the synthesis of certain compounds from the test sample and examination of their mesomorphic behavior. The prediction of the mesomorphism is negative for only three of the 39 compounds considered. The majority of the molecules under consideration tend to form columnar supramolecular packings, and the capability to form a nematic phase is predicted for only eight compounds. For a number of structures, the capability and incapability to form a nematic phase are equally probable. Synthesis and examination of the mesomorphic behavior of seven repesentatives of the series considered showed good agreement with the prediction results. 1,3,5-Tri(4-heptyloxybenzoyloxy)benzene, 1,3,5-tri(4-cyclohexylbenzoyloxy) benzene, 1,3,5-tri(4-nonyloxyphenylcarboxy)-benzene, and 1,2,3-tri(4- cyclohexylbenzoyloxy)benzene pass into the liquid crystal state forming mainly columnar supramolecular packings. 1,3,5-Tri(4-octyloxybenzoyloxy)benzene and 1,3,5-tri(4-nonyloxybenzoyloxy)benzene melt at 55 and 48°C, respectively, without forming a mesophase, which is also well consistent with the prediction results. Pleiades Publishing, Inc., 2006.

Visible-Light-Induced Catalyst-Free Carboxylation of Acylsilanes with Carbon Dioxide

Intermolecular carbon-carbon bond formation between acylsilanes and carbon dioxide (CO2) was achieved by photoirradiation under catalyst-free conditions. In this reaction, siloxycarbenes generated by photoisomerization of the acylsilanes added to the C═O bond of CO2 to give α-ketocarboxylates, which underwent hydrolysis to afford α-ketocarboxylic derivatives in good yields. Control experiments suggest that the generated siloxycarbene is likely to be from the singlet state (S1) of the acylsilane and the addition to CO2 is not in a concerted manner.

Cyclized berberine derivative as well as preparation method and application of cyclized berberine derivative

The invention provides a cyclized berberine derivative as well as a preparation method and application of the cyclized berberine derivative. The compound has a structure as shown in a formula I, wherein a symbol as shown in the specification shows a single bond or double bonds; X is a negative ion; m is equal to 0 or 1; Q is N or N+; and R is OR1, NHR2 or oxo. The compound provided by the invention has excellent activity of resisting to gram-positive bacteria and particularly methicillin (vancomycin)-resistant staphylococcus aureus.